Table 1.
Protein expression of luminal and basal markers in CIS
| All CIS cases | Median | |
|---|---|---|
| n = 156 (100%) | ||
| CK20 | ||
| Positive | 132 (85%) | Positive |
| Negative | 24 (15%) | |
| Her2 | ||
| 0–1 | 55 (35%) | 2 |
| 2 | 51 (33%) | |
| 3 | 50 (32%) | |
| ERβ | ||
| 0–2 | 18 (12%) | 12 |
| 3–12 | 138 (88%) | |
| GATA3 | ||
| 0–2 | 5 (3%) | 12 |
| 3–12 | 151 (97%) | |
| CK5/6 | ||
| Positive | 3 (2%) | Negative |
| Negative | 153 (98%) | |
| CK14 | ||
| Positive | 2 (1%) | Negative |
| Negative | 154 (99%) | |
Overview of protein expression of luminal and basal markers in a cohort of 156 CIS cases. Cytokeratin (CK) 20, GATA3, human epidermal growth factor receptor 2 (Her2), and estrogen receptor (ER) β are luminal markers; CK5/6 and CK14 are basal markers. For CK 20, CK5/6, and CK14, percentage of positive cells was determined, and tumors were considered positive if > 50% of cells expressed the CK. GATA3 expression was scored with the Dako score; Her2 and ERβ expression was scored with the Remmele score